2. Academic Validation
  3. First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone Disease

First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone Disease

  • Oncologist. 2019 Mar;24(3):303-e102. doi: 10.1634/theoncologist.2018-0707.
Shawn Patrick Zinnen 1,  Alexander Karpeisky 2,  Daniel D Von Hoff 3,  Larisa Plekhova 4,  Alexander Alexandrov 5
Affiliations

Affiliations

  • 1 MBC Pharma Inc., Aurora, Colorado, USA szinnen@mbcpharma.com.
  • 2 MBC Pharma Inc., Aurora, Colorado, USA.
  • 3 Translational Genomics Research Institute (TGEN), Phoenix, Arizona, USA.
  • 4 Osteros Biomedica Ltd., Moscow, Russia.
  • 5 Maxwell Biotech Group, Moscow, Russia.
PMID: 30413669 DOI: 10.1634/theoncologist.2018-0707
Figures
Products